Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theralase TechnologiesTLTFF -0.44%45 3-1 Month Momentum % is -32.93% as of Jul. 23, 2026. GuruFocus rates TLTFF with a GF Score™ of 45/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 85.26% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-23), Theralase Technologies's 3-1 Month Momentum % is -32.93%.
The industry rank for Theralase Technologies's 3-1 Month Momentum % or its related term are showing as below:
TLTFF's 3-1 Month Momentum % is ranked worse than 85.26% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: -10.37
vs TLTFF: -32.93
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Theralase Technologies 3-1 Month Momentum % Related Terms
TLTFF vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Theralase Technologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a 3-1 Month Momentum % of -32.93% as of Jul. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Theralase Technologies and its competitors. According to the industry distribution chart, Theralase Technologies ranks #717 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 85.3%.
Is Theralase Technologies' 3-1 Month Momentum % too high?
Theralase Technologies' current 3-1 Month Momentum % is -32.93%. Based on the distribution chart, Theralase Technologies ranks #717 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #717 out of 841 companies for 3-1 Month Momentum %. This places Theralase Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current 3-1 Month Momentum % is -32.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.19 — trading 42.3% above its estimated fair value. The current 3-1 Month Momentum % is -32.93%. Theralase Technologies' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current 3-1 Month Momentum % is -32.93% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.19 is trading 42.3% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TLTFF:
3-1 Month Momentum %: -32.93%
GF Value™: $0.13 vs. price of $0.19 (42.3% above fair value)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
45GF Score
Get the complete analysis for TLTFF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
